Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis

Boehringer Ingelheim reported positive Phase III results for survodutide, a glucagon/GLP-1 dual agonist, demonstrating up to 16.6% weight loss, 34% visceral fat reduction, and 63% liver fat reduction in people with obesity. The SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials met primary endpoints, with additional Phase IIIb studies planned to evaluate the drug in women's health, cardiac function, and real-world treatment approaches.